
Sign up to save your podcasts
Or


In this week's episode we'll learn about the updated phase 3 results on fixed-dose venetoclax plus obinutuzumab in previously untreated CLL. Then, we'll hear about dual epi-immunotherapy in classical Hodgkin lymphoma. Finally we'll explore redefining risk of treatment failure in CML.
Featured Articles:
By American Society of Hematology4.1
4949 ratings
In this week's episode we'll learn about the updated phase 3 results on fixed-dose venetoclax plus obinutuzumab in previously untreated CLL. Then, we'll hear about dual epi-immunotherapy in classical Hodgkin lymphoma. Finally we'll explore redefining risk of treatment failure in CML.
Featured Articles:

11,147 Listeners

140 Listeners

318 Listeners

499 Listeners

75 Listeners

26 Listeners

1,157 Listeners

2 Listeners

363 Listeners

373 Listeners

1 Listeners

48 Listeners

190 Listeners

30 Listeners

4 Listeners